Stock Track | Mineralys Therapeutics Soars 5.22% as Multiple Analysts Raise Price Targets

Stock Track11-11

Shares of Mineralys Therapeutics, Inc. (MLYS) are soaring 5.22% in Tuesday's trading session, buoyed by a wave of positive analyst actions. Several prominent financial institutions have reiterated their bullish stance on the company while significantly raising their price targets, indicating strong confidence in Mineralys' future prospects.

Leading the charge, Jefferies has increased its target price for MLYS from $26 to $42, representing a substantial 61.5% upside. Wells Fargo followed suit, raising its price target from $50 to $55 while maintaining a Buy rating. Stifel Nicolaus and LifeSci Capital have also reaffirmed their Buy ratings, with price targets set at $45 and $54, respectively. These upgrades suggest that analysts see considerable growth potential in Mineralys Therapeutics' business model and pipeline.

The collective bullish sentiment from multiple analysts is likely driving investor enthusiasm, contributing to the stock's significant intraday gain. As Mineralys Therapeutics continues to attract positive attention from Wall Street, investors will be closely watching for any developments that could further support the company's valuation and growth trajectory.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1172176481?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-11 23:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1172176481","market":"nz","top_or_hot":-1,"title":"Stock Track | Mineralys Therapeutics Soars 5.22% as Multiple Analysts Raise Price Targets","media":"Stock Track","content":"<p>Shares of Mineralys Therapeutics, Inc. (MLYS) are soaring 5.22% in Tuesday's trading session, buoyed by a wave of positive analyst actions. Several prominent financial institutions have reiterated their bullish stance on the company while significantly raising their price targets, indicating strong confidence in Mineralys' future prospects.</p>\n\n<p>Leading the charge, Jefferies has increased its target price for MLYS from $26 to $42, representing a substantial 61.5% upside. Wells Fargo followed suit, raising its price target from $50 to $55 while maintaining a Buy rating. Stifel Nicolaus and LifeSci Capital have also reaffirmed their Buy ratings, with price targets set at $45 and $54, respectively. These upgrades suggest that analysts see considerable growth potential in Mineralys Therapeutics' business model and pipeline.</p>\n\n<p>The collective bullish sentiment from multiple analysts is likely driving investor enthusiasm, contributing to the stock's significant intraday gain. As Mineralys Therapeutics continues to attract positive attention from Wall Street, investors will be closely watching for any developments that could further support the company's valuation and growth trajectory.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Mineralys Therapeutics Soars 5.22% as Multiple Analysts Raise Price Targets</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Mineralys Therapeutics Soars 5.22% as Multiple Analysts Raise Price Targets\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-11 23:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Mineralys Therapeutics, Inc. (MLYS) are soaring 5.22% in Tuesday's trading session, buoyed by a wave of positive analyst actions. Several prominent financial institutions have reiterated their bullish stance on the company while significantly raising their price targets, indicating strong confidence in Mineralys' future prospects.</p>\n\n<p>Leading the charge, Jefferies has increased its target price for MLYS from $26 to $42, representing a substantial 61.5% upside. Wells Fargo followed suit, raising its price target from $50 to $55 while maintaining a Buy rating. Stifel Nicolaus and LifeSci Capital have also reaffirmed their Buy ratings, with price targets set at $45 and $54, respectively. These upgrades suggest that analysts see considerable growth potential in Mineralys Therapeutics' business model and pipeline.</p>\n\n<p>The collective bullish sentiment from multiple analysts is likely driving investor enthusiasm, contributing to the stock's significant intraday gain. As Mineralys Therapeutics continues to attract positive attention from Wall Street, investors will be closely watching for any developments that could further support the company's valuation and growth trajectory.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MLYS","symbol_name":"Mineralys Therapeutics, Inc.","start_time":0,"source_url":"","article_id":"1172176481","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1172176481","pubTimestamp":1762873580,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Mineralys Therapeutics, Inc. (MLYS) are soaring 5.22% in Tuesday's trading session, buoyed by a wave of positive analyst actions. Several prominent financial institutions have reiterated...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MLYS":"Mineralys Therapeutics, Inc."},"translate_title":"个股追踪|Mineralys Therapeutics大涨5.22%多位分析师上调目标价","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MLYS":1},"content_text":"Shares of Mineralys Therapeutics, Inc. (MLYS) are soaring 5.22% in Tuesday's trading session, buoyed by a wave of positive analyst actions. Several prominent financial institutions have reiterated their bullish stance on the company while significantly raising their price targets, indicating strong confidence in Mineralys' future prospects.\nLeading the charge, Jefferies has increased its target price for MLYS from $26 to $42, representing a substantial 61.5% upside. Wells Fargo followed suit, raising its price target from $50 to $55 while maintaining a Buy rating. Stifel Nicolaus and LifeSci Capital have also reaffirmed their Buy ratings, with price targets set at $45 and $54, respectively. These upgrades suggest that analysts see considerable growth potential in Mineralys Therapeutics' business model and pipeline.\nThe collective bullish sentiment from multiple analysts is likely driving investor enthusiasm, contributing to the stock's significant intraday gain. As Mineralys Therapeutics continues to attract positive attention from Wall Street, investors will be closely watching for any developments that could further support the company's valuation and growth trajectory.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.10","shortVersion":"4.35.10","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1172176481","isCrawlerRequest":true}